<p><img src="data:image/jpeg;base64,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" alt="image">
<img src="data:image/jpeg;base64,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" alt="image">
<img src="data:image/jpeg;base64,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" alt="image">
Neuroscience and Biobehavioral Reviews 163 (2024) 105774
Available online 22 June 2024 0149-7634/ 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (<a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>).
Review article
Treatments in the pipeline for attention-deficit/hyperactivity disorder (ADHD) in adults
Guilherme Fusetto Veronesi a,1, Alessandra Gabellone b,1, Anneka Tomlinson c,d, Marco Solmi e,f,g,h,i, j, Christoph U. Correll i,k, l,m,n, Samuele Cortese j,n,o,p,q,*
a  <em>Southern Health NHS Foundation Trust, UK</em> b  <em>DiBraiN-Department of Translational Biomedicine Neurosciences, University of Bari &#34;Aldo Moro&#34;, Bari, Italy</em> c  <em>Department of Psychiatry, University of Oxford, Oxford, UK</em> d  <em>Oxford Health NHS Foundation Trust, Oxford, UK</em> e  <em>Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada</em> f  <em>Department of Mental Health, The Ottawa Hospital, Ottawa, ON, Canada</em> g  <em>Ottawa Hospital Research Institute (OHRI) Clinical Epidemiology Program, University of Ottawa, Ottawa, ON, Canada</em> h  <em>School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada</em> i  <em>Department of Child and Adolescent Psychiatry, Charit Universittsmedizin, Berlin, Germany</em> j  <em>Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK</em> k  <em>The Zucker Hillside Hospital, Department of Psychiatry, Glen Oaks, NY, USA</em> l  <em>Department of Psychiatry and Molecular Medicine, Donald and Barbara School of Medicine at Hofstra/Northwell, Hempstead, NY, USA</em> m  <em>German Center for Mental Health (DZPG), partner site Berlin, Germany</em> n  <em>Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK</em> o  <em>Solent NHS Trust, Southampton, UK</em> p  <em>Hassenfeld Childrens Hospital at NYU Langone, New York University Child Study Center, New York City, NY, USA</em> q  <em>DiMePRe-J-Department of Precision and Rigenerative Medicine-Jonic Area, University of Bari &#34;Aldo Moro&#34;, Bari, Italy</em>
A R T I C L E  I N F O
<em>Keywords:</em> ADHD Adults Pipeline Pharmacological Non-pharmacological RCT
A B S T R A C T
To provide an overview of treatments in the pipeline for adults with attention-deficit/hyperactivity disorder (ADHD), we searched <a href="https://clinicaltrials.gov/and">https://clinicaltrials.gov/and</a> and <a href="https://www.clinicaltrialsregister.eu/">https://www.clinicaltrialsregister.eu/</a> from 01/01/ 201010/18/2023 for ongoing or completed phase 2 or 3 randomised controlled trials (RCTs), assessing phar-macological or non-pharmacological interventions for adults with ADHD with no current regulatory approval. We found 90 eligible RCTs. Of these, 24 (27 %) reported results with statistical analysis for primary efficacy endpoints. While several pharmacological and non-pharmacological interventions had evidence of superiority compared to the control condition from a single RCT, centanafadine (norepinephrine, dopamine, and serotonin re-uptake inhibitor) was the only treatment with evidence of efficacy on ADHD core symptoms (small effect  $size=0.280.40) replicated in at least one additional RCT, alongside reasonable tolerability. Overall, the body of$ ongoing RCTs in adults with ADHD is insufficient, without any intervention on the horizon to match the efficacy of stimulant treatment or atomoxetine and with better tolerability profile. Additional effective and well tolerated treatments for adults with ADHD require development and testing.
<strong>1. Introduction</strong>
Attention-deficit/hyperactivity disorder (ADHD) is characterised by developmentally inappropriate and impairing inattention plus
hyperactivity and/or impulsivity (Faraone et al., 2024). ADHD is the most common neurodevelopmental disorder, affecting around 5 % of school-aged children worldwide according to a re-analysis of the Global Burden of Disease (GBD) data (Cortese et al., 2023) and 8 %, with an</p>
<ul>
<li>Correspondence to: Centre for Innovation in Mental Health (CIMH), Faculty of Environmental and Life Sciences, University of Southampton, Highfield Campus, Building 44, Southampton SO17 1BJ, UK
<em>E-mail address: <a href="mailto:samuele.cortese@soton.ac.uk">samuele.cortese@soton.ac.uk</a> (S. Cortese).</em> 1 These authors share the first authorship
Contents lists available at ScienceDirect
Neuroscience and Biobehavioral Reviews
journal homepage: <a href="http://www.elsevier.com/locate/neubiorev">www.elsevier.com/locate/neubiorev</a>
<a href="https://doi.org/10.1016/j.neubiorev.2024.105774">https://doi.org/10.1016/j.neubiorev.2024.105774</a> Received 6 April 2024; Received in revised form 4 June 2024; Accepted 14 June 2024
<em>Neuroscience and Biobehavioral Reviews 163 (2024) 105774</em>
uneven gender distribution of 10 % for males and 5 % for females, based on an umbrella review including five systematic reviews and meta-analyses (57 unique primary studies) (Ayano et al., 2023).
Impairing symptoms of ADHD persist into adulthood in up to 75 % of the cases (Sibley et al., 2016), with an estimated prevalence of ADHD in adults at around 2.5 % (Song et al., 2021). ADHD is often comorbid with other disorders, including mood, anxiety, and substance use disorders, or dysfunctions, such as emotional dysregulation and executive dysfunction (Faraone et al., 2021), as well as physical disorders, including obesity and asthma (Arrondo et al., 2022).
Treatment options proposed for ADHD include pharmacological - encompassing stimulant and non-stimulant medications - and non- pharmacological interventions (Cortese, 2020). In currently available guidelines, pharmacotherapy plays an important role in the management of ADHD in adults. For instance, the 2018 (updated in 2019) National Institute for Healthcare and Excellence (NICE) guidelines (National Institute For Health and Care Excellence (NICE), 2019) suggested that medication (stimulants as first line, followed by the non-stimulant atomoxetine) should be offered after environmental modifications (such as reducing noise or distractions) have been implemented but ADHD symptoms are still impairing. Current medications for ADHD in adults are efficacious, albeit with lower effect sizes compared to children, especially in relation to stimulants for which effects sizes have been found to be high in children and medium in adults (Cortese et al., 2018). However, there are concerns around the safety of currently available ADHD medications, including their possible cardiovascular effects (Cortese and Fava, 2024) and limited abuse potential - even though the risk-benefit profile in general favours the use of medications, as recently highlighted by the ADDUCE project, a naturalistic, longitudinal, controlled study in 27 Eu-ropean child and adolescent mental health centres (e.g., Buitelaar et al., 2022). Therefore, there is a need for additional efficacious and safer medications for adults with ADHD.
In addition to pharmacological treatments, current guidelines include also non-pharmacological options. For instance, the NICE guidelines recommend considering non-pharmacological treatments if they are the preferred choice by the patient, medications are not well tolerated or ineffective, or regular adherence to medication is difficult. It remains unclear to what extent non-pharmacological options are effi-cacious and effective to tackle ADHD core symptoms or associated problems, such as emotional dysregulation. Of note, an increasing number of randomised controlled trials (RCTs) are testing the efficacy of non-pharmacological treatments, including psychotherapy, diet changes, cognitive training, and neurostimulation, for adult ADHD. Therefore, gaining insight into promising pharmacological and non- pharmacological treatment for adults with ADHD is crucial to inform future guidelines.
A previous study systematically reviewed 939 phase 2 or 3 RCTs testing medications for adults with mental health conditions, but ADHD was outside the scope of that work (Correll et al., 2023). Another study (Cortese et al., 2023b) systematically reviewed 234 phase 2 or 3 RCTs of medications without regulatory approval in the US, Europe or Asia, including also RCTs of dietary interventions/probiotics, as well as phase 4 RCTs of agents targeting unlicensed indications for child-ren/adolescents with mental health disorders, including ADHD, but was limited to children and to pharmacological treatments. The present re-view builds on those two previous studies and complements them by systematically searching for phase 2, 3, 4 RCTs of non-approved phar-macological and non-pharmacological interventions for adults with ADHD. The present review is expected to provide a comprehensive overview of treatments in the pipeline for adult ADHD inform future research priorities in the field.
<strong>2. Methods</strong>
The study protocol is available in Open Science Framework, OSF (htt ps://osf.io/dnmr7/).
<em>2.1. Search strategy</em>
We searched <a href="https://clinicaltrials.gov/and">https://clinicaltrials.gov/and</a> and <a href="https://www.clinica">https://www.clinica</a> ltrialsregister.eu/ from 01/01/201010/18/2023. The time frame is very similar to the one considered in a recent similar review on phase 2/ 3 RCTs of psychopharmacological agents in adults (Correll et al., 2023). We also conducted an additional systematic targeted search in PubMed to check if identified RCTs for which results were not available in the clinical trials platforms had been published. The following filters were used for the search in clinicaltrials.gov: 1) study type: interventional studies (Clinical Trials); 2) recruitment: any available option (not yet recruiting/recruiting/enrolling by invitation/active, not recrui-ting/terminated/completed/unknown status); 3) age group: adults; 4) phase: phase 2/phase 3 or 4; 5) study start: From 01/01/2010 (assuming  $that if studies initiated 13 years ago and results had not been published$ or no additional studies were ongoing that this trial program had been discontinued). Likewise, the following filters were used for the search in <a href="https://www.clinicaltrialsregister.eu/">https://www.clinicaltrialsregister.eu/</a>: 1) select trial status: com-pleted/ongoing/restarted; 2) age range: adults; 3) select trial phase: phase two/phase three/phase four; and 4) select date range: 01/01/201010/18/2023 (with the same reasoning for the cut-off date as mentioned for clinicaltrials.gov).
<em>2.2. Inclusion and exclusion criteria</em>
We included ongoing or completed phase 2 or 3 RCTs, regardless of their level of blinding, assessing pharmacological or non- pharmacological interventions for adults with ADHD that had to the best of our knowledge no regulatory approval in the US, Europe (through EMA licensing procedures, not those approved by individual countries through national licensing procedures) or Asia as of 10/18/ 2023. We also aimed to include any phase 4 RCTs of non- pharmacological treatments and, for pharmacological treatments, of medications, if any, already approved for adults with ADHD but tar-geting a currently unapproved indication (e.g., emotional dysregulation as primary outcome).
<em>2.3. Classification of the mechanisms of action of the tested medications</em>
To describe the possible mechanisms of action of the tested medi-cations, we referred, whenever possible to the Neuroscience based Nomenclature (NbN) website (<a href="https://nbn2r.com/">https://nbn2r.com/</a>).
<em>2.4. Evaluation of the chances of success</em>
After summarizing the search results, we highlighted those in-terventions that were considered to be most promising based on the current level of evidence with regard to i) positive phase 2 and/or phase 3 or 4 clinical trials indicating superiority vs. placebo/other control. In particular, we assessed i) whether there were treatments with at least two positive RCTs (on the primary outcomes) without any negative RCTs (on the primary outcomes); ii) magnitude of the observed effect, with reference to the benchmarks suggested by Cohen (Cohen, 1988): 0.2: small; 0.5: medium; 0,8: large effect size; iii) demonstration of minimum requirements for safety/tolerability, in terms of lack of severe adverse events as defined by the Food and Drug Administration (FDA), i.e., those: resulting in death, or life threatening, or requiring inpatient hospitalisation or causing prolongation of existing hospitalisation, or resulting in persistent or significant disability/incapacity, or contrib-uting to a congenital anomaly/birth defect, or requiring intervention to prevent permanent impairment or damage.
<em>G.F. Veronesi et al.</em>
<em>Neuroscience and Biobehavioral Reviews 163 (2024) 105774</em>
<strong>3. Results</strong>
<em>3.1. Overview of included RCTs</em>
We initially identified 115 potentially eligible RCTs (Table S1). However, 25 of the RCTs of pharmacological treatments tested medi-cations already approved for adults with ADHD for core symptoms of ADHD (Table S2), which will not be discussed further in the present  $article. Of the remaining 90 RCTs, around 27 % (n =$ 24) reported results with statistical analysis for primary efficacy endpoints; in the rest (73 %,  $n =$ 66), results with statistical analysis of significance were not re-ported/available (ongoing trials: 38 %, completed trials: 38 %, unknown status: 14 %, terminated: 4 %, not yet recruiting: 6 %).
Completed RCTs with positive results on at least one primary  $outcome (n =$ 26) and those with negative results on every primary  $outcome (n =$ 8) are reported in Table 1 (pharmacological treatment) and Table 2 (non-pharmacological treatment). When available, Tables 12 report also data on tolerability, in terms of percentage of participants who dropped out due to adverse events or those who experienced adverse events defined as serious by the study authors, in line with the above-mentioned FDA classification.
<em>3.2. Pharmacological treatments</em>
Agents for which results of statistical analysis were available are descried below, in alphabetical order.
<em>3.2.1. Centanafadine</em> Centanafadine is a compound that acts by inhibiting the reuptake of
norepinephrine, dopamine, and serotonin. Its sustained release (SR) formulation was investigated in two phase III, multicentre studies con-ducted contemporaneously (Adler et al., 2022). In the first trial (NCT03605680), 466 (48.7 % females) adults with ADHD were rando-mised, following a 1-week single-blind run-in period, to receive cen-tanafadine SR 200 mg/day, 400 mg/day, or placebo. At day 42, efficacy was assessed according to the change from baseline in the ADHD Investigator Symptom Rating Scale (AISRS). Both active arms showed superiority against placebo. Least Square mean differences (95 % CI) versus placebo for the 200 mg/day and 400 mg/day groups were,  $respectively,  3.1 ([-5.79,  0.51]; p = 0.0193; effect size = $ 0.28) and  $ 2.74 ([-5.35,  0.14]; p = 0.0392; effect size = $ 0.24).
The second trial (NCT03605836) utilised the same design and had a total of 440 participants (47 % females) randomised to treatment. Measurement of change from baseline in AISRS total score at the end of week six also showed superiority of centanafadine SR over placebo for both 200 mg/day and 400 mg/day dose groups. Respectively, LS mean  $differences were reported as  4.01 ([-6.55,  1.46]; p =$ 0.0021; effect  $size =  0.37) and  4.47 ([-7.02,  1.82]; p = 0.0009; effect size = $ 0.40).
In both studies, adverse effects (AEs) were more frequent in the  $active groups (200 mg/day = 25.2 %; 400 mg/day =$ 31.8 %) than in controls (17.6 %), although most were mild or moderate in severity. Of the AEs deemed to be possibly related to centanafadine, the most com-mon AEs were decreased appetite, headache, dry mouth, and nausea. Discontinuation due to treatment-emergent AEs (TEAEs) was also higher  $in the active (200 mg/day = 4.8 %; 400 mg/day =$ 6.2 %) than in the placebo arm (1.4 %).
An earlier, phase IIb study (NCT02547428), reported in Wigal et al. (2020), had previously evaluated the efficacy of centanafadine SR in 85 adults (44 % females) with ADHD utilising a crossover design. Patients were allocated to either placebo or centanafadine SR (400800 mg/day) and received three weeks of treatment before crossing over to the opposite treatment assignment. Change in ADHD Rating Scale-IV (ADHD-RS-IV) score from baseline to week 3 showed superiority of  $centanafadine SR against placebo (LS mean difference [CI 95 %]: $ 8.1  $[-11.0,  5.1]; p &lt; 0.001; effect size =$ 0.66). Eighty percent of patients
receiving centanafadine SR experienced an AE, compared with 68 % in the placebo group. In the centanafadine SR group, TEAEs were, in descending order of occurrence, decreased appetite, headache, and nausea. Out of the twelve patients that discontinued treatment due to a  $TEAE (centanafadine: n = 11; placebo: n =$ 1), ten had received 600 mg or more of centanafadine SR within one day of AE onset.
<em>3.2.2. Dasotraline</em> A multicentre RCT including 636 adults (39.6 % females) with ADHD
(NCT02276209) (Adler et al., 2021) investigated the efficacy of daso-traline, a pharmacologic agent that potently inhibits dopamine and norepinephrine transporters presynaptically (Adler et al., 2021). Sub-jects were allocated on a 1:1:1 ratio to treatment with dasotraline 4 or 6 mg/day, or placebo. At the end of week 8, change in severity of ADHD symptoms as measured by the ADHD Rating Scale, Version IV, total score showed no significant improvement in the active groups when compared to placebo when corrected using Hochbergs procedure  $([dasotraline 4 mg/day vs. placebo:  15.0 vs.  13.9; p =$ n.s.; effect  $size: 0.09]; [dasotraline 6 mg/day vs. placebo:  16.5 vs. $ 13.9;  <em>$P =</em>$ 0.074; effect size: 0.23]). For non-adjusted p-values, dasotraline  $6 mg/day was significantly better than placebo (p =$ 0.037). AEs were more common in the combined dasotraline dose group (80.1 %) than in the placebo arm (62.6 %). The most common AEs in the former group were insomnia, decreased appetite, dry mouth, and anxiety. Psychosis and mania-related events happened in two patients in the dasotraline 4 mg/day group, four patients in the Dasotraline 6 mg/day group and two in those taking placebo.
<em>3.2.3. L-methylfolate supplementation</em> L-methylfolate is a folate derivative which is transported across the
blood brain barrier and acts as an important factor in the synthesis of monoaminergic neurotransmitters such as norepinephrine and dopa-mine (Lam et al., 2022). A pilot study (NCT01853280) evaluated the effect of L-methylfolate supplementation to OROS-methylphenidate pharmacotherapy in adults with ADHD. Following randomisation, 44 patients (61.4 % females) received treatment with either 15 mg/day of L-methylfolate plus OROS methylphenidate or OROS methylphenidate with matched placebo comparator, for a period of twelve weeks. The mean change in score from baseline in the AISRS at week 12 was slightly greater in the treatment (-22.9, with a standard deviation of 10.4) than in the control arm (-20.8, with a standard deviation of 11.3); however, no additional statistical analyses were reported. No serious adverse events were reported. Other (not serious) adverse events that included headache, insomnia, mucosal dryness, decreased appetite and nausea, vomiting and diarrhoea were reported in 20/22 and 19/22 of the par-ticipants in the active and control group, respectively.
<em>3.2.4. Mazindol</em> One study (NCT02808104) (Wigal et al., 2018) investigated the ef-
ficacy of a controlled-release (CR) formulation of mazindol, a drug previously marketed for short-term treatment of obesity which acts by blocking the reuptake of dopamine and noradrenaline, for adult ADHD. Seventy-five patients (57 % females) completed six weeks of treatment with either placebo or 13 mg/day of mazindol CR. At the end of week 6, a significant decrease in the ADHD-RS-DSM5 score was seen in the  $intervention group when compared to placebo (-18.9 vs. $ 5.7; LS mean  $difference [95 % CI]:  13.2 [-18.7, $  <em>$7.6]; p &lt;</em>$ 0.001), with an overall placebo-corrected effect size of 1.09 in the intention-to-treat population. The group taking mazindol CR experienced more dry mouth, nausea, fatigue, increased heart rate, decreased appetite and constipation than the one allocated to placebo, with no serious treatment-emergent adverse events.
<em>3.2.5. Metadoxine</em> The efficacy of metadoxine - a selective antagonist of the serotonin
receptor subtype 5-HT 2b - in decreasing ADHD symptoms in
<em>G.F. Veronesi et al.</em>
<em>NeuroscienceandBiobehavioralReviews163(2024)105774</em>
4
Completed RCTs of pharmacological treatments with positive results on at least one primary outcome and those with negative results on every primary outcome.
title Intervention (dose) mechanism of action total n of arms control total n subjects
age range
trial duration
funding/ manufacturer
phase NCT/EudraCT number
country start date
status descriptive results (primary outcome)
Tolerability
Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/ Hyperactivity Disorder (MJ- ADHD)
Adderall-XR [80 mg/day]
dopamine, norepinephrine reuptake inhibitor (DAT, NET), releaser (DA, NE)
2 arms: placebo vs Adderall-XR
placebo  33 18 Years to 65 Years (Adult, Older Adult)
12w New York State Psychiatric Institute
2;3 NCT02803229 United States
2016.07 COMPLETED WITH RESULTS
Superior Serious adverse events:  $7.69 % (n =$ 1) in Adderall-XR group
Real-World Evidence of Duration of Effect of Adhansia XR (Extended- Release) for Treatment of Attention-Deficit/ Hyperactivity Disorder (ADHD) (RE-DAX)
Adhansia XR - Methylphenidate extended-release capsules taken once daily [25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg]
dopamine, norepinephrine reuptake inhibitor (DAT, NET), releaser (DA, NE)
2 arms: Adhansia XR vs Concerta
Cconcerta, once daily (18 mg, 27 mg, 36 mg, and 54 mg)
267 12 Years and older (Child, Adult, Older Adult)
8w Purdue Pharma LP 4 NCT04507204 United States
2020.07 COMPLETED WITH RESULTS
Superior Serious adverse events:  $2.26 % (n =$ 3) in Adhansia XR group;  $2.99 % (n =$ 4, including one death) in Concerta group
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
Amphetamine Sulfate [20 mg/ day, 40 mg/day]
dopamine, norepinephrine reuptake inhibitor (DAT, NET), releaser (DA, NE)
3 arms 1) 20 mg/ day Amphetamine Sulfate arm; 2) 40 mg/day Amphetamine Sulfate arm 3) Placebo
placebo  320 18 Years to 55 Years (Adult)
5w Arbor Pharmaceuticals, Inc.
3 NCT03659929 United States
2018.09 COMPLETED Superior:  $p &lt;$ 0.001 for both 20 mg/ day and 40 mg/day
Atomoxetine in Veterans With Comorbid ADHD/ PTSD
Atomoxetine [80 MG]
norepinephrine reuptake inhibitor (NET)
2 arms, Atomoxetine 80 MG vs placebo
placebo  44 20 Years to 60 Years (Adult)
10w VA Office of Research and Development
4 NCT02287038 United States
2014.10 COMPLETED WITH RESULTS
Superior:  $p =$ 0.017
Discontinuation of treatment due to side  $effects: n =$ 1 atomoxetine phase Serious adverse events: nil observed
A Trial Evaluating the Efficacy, Safety, &amp; Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention- deficit/ Hyperactivity Disorder
Centanafadine [Centanafadine SR 200 mg; Centanafadine SR 400 mg]
inhibits the reuptake of norepinephrine, dopamine, and serotonin
4 arms: 1)Single- blind treatment with Placebo; 2) Double-blind Treatment with Centanafadine SR 200 mg; 3) Double- blind Treatment with Centanafadine SR 400 mg; 4) Double- blind Treatment with Placebo
placebo  604 18 Years to 55 Years (Adult)
6w Otsuka Pharmaceutical Development &amp; Commercialization, Inc.
3 NCT03605680; PMID: 35652746
United States
2019.01 COMPLETED WITH RESULTS
Superior: 200 mg/day:  $p =0.0193,$ effect size  $$ 0.28; 400 mg/day:  $p =$ 0.0392, effect size  $$ 0.24
Discontinuation of treatment due to side effects (results pooled with study NCT3605836): 4.8 %  $(n =$ 14) in centanafadine 200 mg/day group,  $6.2 % (n =$ 18) in centanafadine 400 mg/day group,  $1.4 % (n =$ 4) in placebo group Serious adverse events (NCT03605680  $only): 1.34 % (n =$ 2) in centanafadine 200 mg/day group
<em>(continued on next page)</em>
<em>.F. Veronesi et al.</em>
<em>NeuroscienceandBiobehavioralReviews163(2024)105774</em>
5
title Intervention (dose) mechanism of action total n of arms control total n subjects
age range
trial duration
funding/ manufacturer
phase NCT/EudraCT number
country start date
status descriptive results (primary outcome)
Tolerability
A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention- deficit/ Hyperactivity Disorder
Centanafadine [Centanafadine SR 200 mg; Centanafadine SR 400 mg]
inhibits the reuptake of norepinephrine, dopamine, and serotonin
4 arms:1) Single- blind tretament with Placebo, 2) Double-blind Treatment with Centanafadine SR 200 mg, 3)Double- blind Treatment with Centanafadine SR 400 mg, 4) Double- blind Treatment with Placebo
placebo  590 18 Years to 55 Years (Adult)
6w Otsuka Pharmaceutical Development &amp; Commercialization, Inc.
3 NCT03605836; PMID: 35652746
United States
2019.01 COMPLETED WITH RESULTS
Superior: 200 mg/day:  $p =$ 0.0021, effect size  $$ 0.37; 400 mg/day:  $p =$ 0.0009, effect size  $$ 0.40
Discontinuation of treatment due to side effects (results pooled with study NCT03605680):  $4.8 % (n =$ 14) in centanafadine 200 mg/day group,  $6.2 % (n =$ 18) in centanafadine 400 mg/day group,  $1.4 % (n =$ 4) in placebo group Serious adverse events (NCT03605836  $only): 0.69 % (n =$ 1) in centanafadine 200 mg/day group
Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention- Deficit Hyperactivity Disorder (ADHD)
Centanafadine Sustained-Release (CTN SR) [CTN SR tablets starting at a dose of 100 or 200 milligrams (mg) on Day 1. Dose was up titrated up to 800 mg daily dose for up to 3 weeks in Period 1. The dose was decreased based on safety and tolerability based on Investigators discretion, followed by a washout Period of 1 week followed by matching-placebo for up to 3 weeks in Period 2. The most common total daily dose (TDD) was 400 mg/day.]
inhibits the reuptake of norepinephrine, dopamine, and serotonin
2 arms: 1) Experimental: CTN SR First, Then Placebo; 2) Experimental: Placebo First, Then CTN SR
placebo  82 18 Years to 60 Years (Adult)
7w Otsuka Pharmaceutical Development &amp; Commercialization, Inc.
2 NCT02547428; PMID: 32606695
United States
2015.08 COMPLETED WITH RESULTS
Superior:  $p &lt;$ 0.001;  $effect size =$ 0.66.
Discontinuation of treatment due to side  $effects: 13.9 % (n =$ 11) in centanafadine  $group, 1.4 % (n =$ 1) in placebo group Serious adverse events: nil observed
Dasotraline Adult ADHD Study
Dasotraline [4 Mg, 6 mg]
serotonin- norepinephrine- dopamine reuptake inhibitor
3 arms: Dasotraline 4 mg vs Dasotraline 6 mg vs placebo
placebo  636 18 Years to 55 Years (Adult)
8w Sumitomo Pharma America, Inc.
3 NCT02276209; PMID: 33724251
United States
2014.12 COMPLETED Not superior for primary outcome: Dasotraline 4 mg/day:  $p =$ n.s.; effect size: 0.09;
Discontinuation of treatment due to side effects: 17.1 % in Dasotraline 4 mg/ day group, 23.2 % in Dasotraline 6 mg/ day group, 3.2 % in placebo group
<em>(continued on next page)</em>
<em>.F. Veronesi et al.</em>
<em>NeuroscienceandBiobehavioralReviews163(2024)105774</em>
6
<em><strong>Table 1 (continued</strong></em> )
title Intervention (dose) mechanism of action total n of arms control total n subjects
age range
trial duration
funding/ manufacturer
phase NCT/EudraCT number
country start date
status descriptive results (primary outcome)
Tolerability
Dasotraline 6 mg/day:  $p =$ 0.074; effect size: 0.23
Serious adverse  $events: n =$ 2 in Dasotraline 4,<a class="g3mark-shortlink" href="https://g.corp.google.com/day">g/day</a>  $group, n =$ 2 in Dasotraline 6 mg/  $day group, n =$ 1 in placebo group
L-methylfolate Supplementation to OROS- Methylphenidate Pharmacotherapy in ADHD Adults
L-methylfolate supplementation to OROS- Methylphenidate pharmacotherapy. L-Methylfolate [15 mg of L- Methylfolate (Deplin) daily for 12 weeks as a supplement to OROS- Methylphenidate],
Methylfolate is a cofactor required for the synthesis of serotonin, norepinephrine, and dopamine. Methylphenidate is a dopamine, norepinephrine reuptake inhibitor (DAT, NET), releaser (DA, NE).
2 arms: L- Methylfolate as a supplement to OROS- Methylphenidate vs placebo with OROS- Methylphenidate
placebo with OROS- Methylphenidate
47 18 Years to 55 Years (Adult)
12w Massachusetts General Hospital
2 and 3
NCT01853280 United States
2014.05 COMPLETED WITH RESULTS
Superior Serious adverse events: nil observed
Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT
Lisdexamfetamine [30 mg with allowed adjustments in increments of 10 mg or 20 mg at weekly intervals. Subjects are initiated on these doses and then they were titrated up by 20 mg with a maximum dose of 70 mg].
prodrug to dextroamphetamine; norepinephrine reuptake inhibitor (DAT, NET), releaser (DA, NE)
2 arms: Lisdexamfetamine first, then placebo second; placebo first, then Lisdexamfetamine second
placebo  38 18 Years to 60 Years (Adult)
10w NYU Langone Health
2 NCT02635035; PMID: 34232582
United States
2015.11 COMPLETED WITH RESULTS
Superior  $Block 1: p=$ 0.01, effect size 0.97;  $Block 2: p=$ 0.007, effect size 0.91
Discontinuation of treatment due to side  $effects: n =$ 1 in the placebo phase, after having done the Lisdexamphetamine phase Serious adverse events: nil observed
Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD
Lisdexamfetamine Dimesylate [40 mg]
prodrug to dextroamphetamine; norepinephrine reuptake inhibitor (DAT, NET), releaser (DA, NE)
2 arms: Lisdexamfetamine Dimesylate vs Placebo
Placebo  22 16 Years to 25 Years (Child, Adult)
2d Gregory Fabiano 4 NCT03446885; PMID: 32297783
United States
2018.04 COMPLETED WITH RESULTS
Superior for completion of work- related tasks:  $p &lt;$ 0.05; effect size 0.39
Serious adverse events: nil observed
Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Mazindol [Dosage starting at 1 mg increasing or decreasing in increments of 1 mg depending on efficacy and tolerability. Maximum dose
releases and blocks reuptake of dopamine and noradrenaline
2 arms: mazindol vs placebo
placebo  84 18 Years to 65 Years (Adult, Older Adult)
6w NLS Pharmaceutics 2 NCT02808104; PMID: 29557078
United States
2016.08 COMPLETED Superior:  $p &lt;$ 0.001, effect size 1.09
Discontinuation of treatment due to side  $effects: n =$ 2 in placebo group Serious adverse events: nil observed
<em>(continued on next page)</em>
<em>.F. Veronesi et al.</em>
<em>NeuroscienceandBiobehavioralReviews163(2024)105774</em>
7
<em><strong>Table 1 (continued</strong></em> )
title Intervention (dose) mechanism of action total n of arms control total n subjects
age range
trial duration
funding/ manufacturer
phase NCT/EudraCT number
country start date
status descriptive results (primary outcome)
Tolerability
during the study is 3 mg taken once daily]
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Attention Deficit/ Hyperactivity)
MG01CI (Metadoxine Immediate- release/Slow- release, Bilayer Caplet) [1400 mg]
increases acetaldehyde dehydrogenase activity, ethanol and acetaldehyde plasma clearance, and urinary elimination of ketones
2 (MG01CI vs placebo)
placebo  300 18 Years to 55 Years (Adult)
6w Alcobra Ltd. 2 and 3
NCT02059642 United States
2014.03 COMPLETED WITH RESULTS
Not superior:  $p =$ 0.13
Serious adverse  $events: 0.68 % (n =$ 1) in placebo group
The Safety and Efficacy of OPC- 64005 in the Treatment of Adult Attention-deficit/ Hyperactivity Disorder
OPC-64005 [During the titration period, participants received OPC- 64005 two 10 milligram (mg) tablets, and one OPC-64005- matching placebo tablet along with two atomoxetine- matching placebo capsules, orally, once daily (QD), from Day 1 up to Day 4. During the treatment period, participants received OPC- 64005 three 10 mg tablets, and two atomoxetine- matching placebo capsules, orally, QD, from Day 5 up to Day 56. The dose was reduced to 20 mg if the 30 mg dose in the treatment period was not tolerable.]
OPC-64005: triple reuptake (SERT, NET, and DAT) inhibitor
3 arms: OPC-64005 vs Atomoxetine vs Placebo
placebo  239 18 Years to 55 Years (Adult)
8w Otsuka Pharmaceutical Development &amp; Commercialization, Inc.
2 NCT03324581 United States
2017.11 COMPLETED WITH RESULTS
Superior against placebo:  $p =$ 0.0101
Serious adverse  $events: 1.30 % (n =$ 1) in OPC-65005 group
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/ Hyperactivity Disorder (ADHD)
PRC-063 [25, 35, 45, 55, 70, 85, or 100 mg]
dopamine, norepinephrine reuptake inhibitor (DAT, NET), releaser (DA, NE)
2 arms: 1) Treatment with PRC-063 (25, 35, 45, 55, 70, 85, or 100 mg) vs Placebo
placebo  288 18 Years to 60 Years (Adult)
1w Purdue Pharma, Canada
3 NCT03618030 United States
2018.08 COMPLETED WITH RESULTS
Superior:  $P =$ 0.0003
Discontinuation of treatment due to side effects: nil during double-bling phase.  $2.5 % (n =$ 7) during open-label, dose optimization phase
<em>(continued on next page)</em>
<em>.F. Veronesi et al.</em>
<em>NeuroscienceandBiobehavioralReviews163(2024)105774</em>
8
title Intervention (dose) mechanism of action total n of arms control total n subjects
age range
trial duration
funding/ manufacturer
phase NCT/EudraCT number
country start date
status descriptive results (primary outcome)
Tolerability
Serious adverse  $events: 0.35 % (n =$ 1) during open-label, dose optimization phase
Experimental Medicine in ADHD - Cannabinoids (EMA-C)
Sativex NA 2 arms Sativex Oromucosal Spray vs Placebo
placebo  30 18 Years to 55 Years (Adult)
6w Kings College London
NA NCT02249299; PMID: 28576350
United Kingdom
2014.08 COMPLETED Not superior for primary outcome:  $p =$ 0.16
Discontinuation of treatment due to side  $effects: 6,67 % (n =$ 1) in Sativex group,  $6,67 % (n =$ 1) in placebo group Serious adverse  $events: 6,67 % (n =$ 1) in Sativex group,  $6,67 % (n =$ 1) in placebo group
A Controlled Study of Solriamfetol for ADHD in Adults
Solriamfetol [75 mg, 150 mg]
dopamine and norepinephrine reuptake inhibitor
2 arms: Solriamfetol vs Placebo
placebo  60 18 Years to 65 Years (Adult, Older Adult)
6w Massachusetts General Hospital
2 and 3
NCT04839562; PMID: 37819836
United States
2021.08 COMPLETED Superior.  $p =.0012,$ effect  $size =$ 1.09
Adverse effects in Solriamfetol group with a minimum 10 % difference when compared to placebo: decreased appetite, headache, gastrointestinal, insomnia, increased energy, cardiovascular, and neurologic symptoms.
Safety and Efficacy Study of SHP465 in Adults Aged 1855 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
SHP465 [12.5 mg up to 37.5 mg]
dopamine, norepinephrine reuptake inhibitor (DAT, NET), releaser (DA, NE)
3 arms: SHP465 12.5 mg; SHP465 37.5 mg; Placebo
placebo  275 18 Years to 55 Years (Adult)
4w Shire 3 NCT02604407 United States
2015.11 COMPLETED WITH RESULTS
Superior: 12.5 mg/  $day: p &lt;$ 0.001, effect  $size =$ 0.67; 37.5 mg/  $day: - p &lt;$ 0.001, effect  $size =$ 1.11
Discontinuation of treatment due to side  $effects: 7.6 % (n =$ 7) in 12.5 mg/day SHP465 group,  $5.6 % (n =$ 5) in 37.50 mg/day SHP465 group Serious adverse events: nil observed
Evaluation of SPN- 812 (Viloxazine Extended-release Capsule) in Adults With ADHD
SPN-812 (Viloxazine Extended-release Capsule)
serotonin norepinephrine modulating agent
2 arms: SPN-812 vs placebo
placebo  374 18 Years to 65 Years (Adult, Older Adult)
6w Supernus Pharmaceuticals, Inc
3 NCT04016779; PMID: 35896943
United States
2019.11 COMPLETED WITH RESULTS
Superior:  $p =$ 0.0040
Discontinuation of treatment due to side effects:  $9.0 % (n =$ 17) in Viloxazine ER group,  $4.9 % (n =$ 9) in placebo group Serious adverse  $events: 1.1 % (n =$ 2) in placebo group
Investigating the Effect of Vortioxetine in
vortioxetine [10 mg, 20 mg tablet]
serotonin reuptake inhibitor, receptor partial agonist (5-
3 arms: vortioxetine 10 mg tablet vs
placebo  227 18 Years to 55
12w H. Lundbeck A/S 2 NCT02327013; PMID: 30843450
United States
2014.12 COMPLETED WITH RESULTS
Not superior: Vortioxetine  $10 mg: p =$
Discontinuation of treatment due to side  $effects: 4.3 % (n =$ 2)
<em>(continued on next page)</em>
<em>.F. Veronesi et al.</em>
<em>Neuroscience and Biobehavioral Reviews 163 (2024) 105774</em>
comparison to placebo was investigated in an RCT (NCT02059642) with 249 adults (53 % females). Groups were randomly assigned to receive either a once-daily dose of metadoxine 1400 mg or placebo, for six weeks. At the end of week 6, no statistically significant change in total ADHD symptom score with adult prompts of the Conners Adult ADHD  $Rating Scale was seen in the two groups (Metadoxine vs. Placebo: $ 12.0  $vs.  9.9; LS mean difference [95 % CI]:  2.1 [-4.870.66]; p =$ 0.1358).
<em>3.2.6. OPC-64005</em> OPC-64005 is a triple reuptake (serotonin transporter, norepineph-
rine transporter, and dopamine transporter) inhibitor whose efficacy and safety in the treatment of adults with ADHD were assessed in a phase II, multicentre clinical trial (NCT03324581). A total of 239 participants (53.1 % females) were randomly assigned to eight weeks of treatment with OPC-64005 (2030 mg/day), atomoxetine (active comparator; 4080 mg/day), or placebo. For the primary outcome, measured as the change from baseline in Conners Adult ADHD Rating Scales-Observer: Screening Version (CAARS-O:SV), OPC-64005 was superior to placebo  $(-19.4 vs.  10.3; mean difference [95 % CI]:  6.61 [-11.6,  1.60]; p =$ 0.0101, effect size: not reported), however no significant difference was  $seen between the OPC-64005 and the atomoxetine arms (19.4 vs. $ 20.2;  $mean difference [95 % CI]: 0.81 [-4.30, 5.92]; p =$ 0.7554).
<em>3.2.7. Sativex</em> One study (NCT02249299) (Cooper et al., 2017) evaluated the effi-
cacy of cannabinoids in 30 adults (50 % females) with ADHD. Following a six-week period of treatment with either placebo or Sativex, an oro-mucosal spray containing 2.7 mg delta-9-tetrahydrocannabinol and 2.5 mg cannabidiol per 100 microlitres, measurement of cognitive per-formance and activity level were carried out utilising the Quantitative Behavioural Test (QbTest). Each participant followed a dosing schedule comprised of a 14-day titration period to find the optimal dose (up to maximum of 14 sprays per day), followed by another 28 days of daily administration of the titrated dose. However, no statistically significant changes in QbTest performance from baseline to day 42 were found  $between the two groups (estimated reduction in scores = $ 0.17 [95 % CI  $ 0.400.07]; p =$ 0.16). Mild adverse events were experienced by three patients on the sativex group, including two reports of light-headedness and one of diarrhoea, all of whom were able to resume and complete treatment. One active group participant reported sudden onset of muscular seizures/spasms and stopped Sativex.
<em>3.2.8. Solriamfetol</em> Solriamfetol, a dopamine and norepinephrine reuptake inhibitor
most commonly used for treatment of sleep disorders, was evaluated in a study with 60 adults (48.3 % females) with ADHD (NCT04839562) (Surman et al., 2023). Subjects were randomised to receive placebo or Solriamfetol (75150 mg/day) for six weeks. Following treatment, pa-tients in the active group had greater improvement in total scores in the ADHD Investigator Symptom Rating Scale (AISRS), starting from week 3  $through week 6 (p = 0.0012; week 6 effect size =$ 1.09). Adverse effects reported by the solriamfetol group with a minimum 10 % difference when compared to placebo included decreased appetite, headache, gastrointestinal, insomnia, increased energy, cardiovascular, and neurologic symptoms.
<em>3.2.9. Vortioxetine</em> Vortioxetine, a multimodal antidepressant, which acts as a serotonin
reuptake inhibitor, receptor agonist (5-HT1A), receptor partial agonist (5-HT1B), and a receptor antagonist (5-HT3), was investigated as a po-tential treatment for ADHD in a twelve week, two-stage study (NCT02327013) (Biederman et al., 2019). Stage I, completed by 181 adults, comprised of six weeks of treatment with vortioxetine 10 or 20 mg/day, or placebo (randomised in a 1:1:3 ratio). Placebo  $non-responders (n =$ 59) were then re-allocated in stage II to another six  <strong>weeks of vortioxetine 10 or 20 mg/day, or placebo (randomised in a Ta</strong>
tit le
In
te rv
en tio
n (d
os e)
m ec
ha ni
sm  o
f a ct
io n
to ta
l n  o
f a rm
s co
nt ro
l to
ta l n
su
bj ec
ts  ag
e ra
ng e
tr ia
l du
ra tio
n fu
nd in
g/
m an
uf ac
tu re
r ph
as e
N CT
/E ud
ra CT
nu
m be
r co
un tr
y st
ar t
da te
st
at us
de
sc ri
pt iv
e re
su lts
(p
ri m
ar y
ou tc
om e)
To le
ra bi
lit y
A du
lt A
D H
D
Pa tie
nt s
H T1
A ),
re ce
pt or
an
ta go
ni st
( 5-
H T3
) vo
rt io
xe tin
e 20
m g
ta bl
et  v
s Pl
ac eb
o ta
bl et
Ye ar
s (A
du lt)</li>
</ul>
<ol start="0">
<li></li>
</ol>
<p>97 2;
Vo
rt io
xe tin
e 20
m g:
p  $=$
0. 60
1
in  V
or tio
xe tin
e 10
m g/
da y
gr ou
p,
9. 1
%  (
n  $=$
4)  in
Vo
rt io
xe tin
e 20
m g/
da
y gr
ou p,
1 .6
%  (
n  $=$
2)  in
p la
ce bo
gr
ou p
Se ri
ou s
ad ve
rs e
ev en
ts : 2
.1  %
(n  $=$
1)
in  V
or tio
xe tin
e 10
m g/
da y
gr ou
p,</p>
<ol>
<li>1
%  (
n  $=$</li>
</ol>
<ol>
<li>in
pl
ac eb
o gr
ou p
N A
: n ot
a pp
lic ab
le
<em>G.F. Veronesi et al.</em>
<em>Neuroscience and Biobehavioral Reviews 163 (2024) 105774</em>
1:1:1 ratio). A total of 151 subjects completed the study. The primary efficacy endpoint, measured as mean scores on Adult ADHD Investigator Symptom Rating Scale (AISRS), did not reveal any significant differ- $ences between the groups (vortioxetine 10 mg vs. placebo =  0.1 [SE = 1.4; p = 0.972]; vortioxetine 20 mg vs placebo = 1.0 [SE = 1.9; p =$ 0.601). TEAEs were more common in the vortioxetine 20 mg group, with nausea and fatigue being the most frequently reported ones in either active group. Suicidal ideation reported by one patient was the only serious adverse event in the active groups.
<em>3.2.10. Compounds in RCTs with results of statistical analysis not reported</em> Non-FDA approved compounds for ADHD core symptoms or other
outcomes in RCTs with results of statistical analysis not reported included: TAK-137 (AMPA receptor potentiator) (note: RCT termi-nated), vayarin (which acts on restoring brain lipid imbalance), meta-doxine (a selective antagonist of the serotonin receptor subtype 5-HT 2b, in addition to the RCT above- in a RCT that was terminated), cen-tanafadine (inhibitor of norepinephrine, dopamine, and serotonin re-uptake, in addition to the two positive RCTs above- in a RCT that was terminated), probiotic, melatonin, oxytocin, tolcapone (specific inhibi-tor of cathechol-O-methyltransferase), contrave (combination of naltrexone, an opioid antagonist, and bupropion, an inhibitor of the neuronal reuptake of dopamine and norepinephrine in a study that was withdrawn), solriamfetol (dopamine and norepinephrine reuptake in-hibitor, in addition to a study with positive results reported above), MM- 120 (a tartrate salt form of lysergide, which is a partial 5-HT2A agonist), PDC-1421 (inhibitor of the norepinephrine plasma membrane transport protein), cannabis oil (note: RCT terminated), zantiva (selective inhi-bition of presynaptic norepinephrine reuptake), and NRCT-101SR (adrenergic receptor agonist).
<em>3.3. Non-pharmacological interventions</em>
Interventions for which results with statistical analysis were avail-able are descried below, grouped by type and presented in alphabetical order.
<em>3.3.1. Dietary interventions</em> A study (NCT03342469) investigated the effects of artificial food
colours (AFCs) on ADHD symptoms in 29 students with ADHD (aged 1824 years, 21 females), following a stable medication dose and fre-quency (ADHD medication or otherwise) for at least 3 months. The di-etary intervention consisted of ingesting six of the most common AFCs (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1 and Blue 2) mixed in choc-olate biscuits or a placebo of chocolate biscuits. The participants un-derwent an electroencephalogram (EEG) and a cognitive test (Adult ADHD Self-Report Scale-V1). Exposure to AFC did not result in any significant changes in ADHD symptoms.
<em>3.3.2. Neurostimulation</em> Of the studies identified, three used neurostimulation as a non-
pharmacological treatment for adults with ADHD. One of these trials (NCT03663179) used transcranial magnetic stimulation (TSM), a non- invasive technique for electromagnetic stimulation of brain tissue. Specifically, the study investigated whether 20 sessions of active TMS targeting the left dorsal prefrontal cortex (DLPFC) could improve ex-ecutive cognitive function in adults with ADHD compared to 20 sessions of sham TMS. To evaluate the efficacy of TSM as an alternative treat-ment for ADHD, only patients who were not receiving pharmacological treatment for ADHD were included. Of the 27 participants (9 males, mean [SD] age: 34.4 [13.0] years), 14 were assigned to active TSM and 13 to sham TSM. The study showed that active TSM did not significantly improve ADHD symptoms, as measured by the Conners Adult ADHD Rating ScaleSelf-Report: Long Version (t-score, mean [SD]: active  $TMS  4.4 [9.4] vs. sham TMS $ 5.1 [7.6]). However, an isolated improvement in sustained attention was found using the Conners
$Continuous Performance Task (mean [SD]: active TMS $ 16.2 [17.6] vs.  $sham TMS $ 4.8 [18.0]. In this study, no serious adverse events were reported.
Transcranial direct current stimulation (tDCS) was investigated in the other two studies. In the first study (NCT04003740), tDCS was used to improve symptoms of inattention in patients with ADHD. Adults with  $ADHD (n =$ 64, 34 males, all without ongoing pharmacological treat-ment for ADHD; mean [SD] age: 38.3 [9.6] years) participated in the study. Participants were randomised to receive tDCS stimulation with active or sham devices. After the first 4 weeks of daily stimulation, the active tDCS group significantly improved in terms of symptoms of  $inattention (p &lt;0.001, effect size: not reported) as measured by the$ clinician administered ADHD Self-Report ScalePart A, Inattention (CASRS-I), compared to the sham treatment. No serious adverse events were recorded during the study.
In another randomised, shamcontrolled, double-blind study (NCT04175028) (Dubreuil-Vall et al., 2021), the cognitive and physio-logical effects of tDCS were investigated in 40 adults with ADHD (aged 1867 years). Before and after each session (in which tDCS targeted the left DLPFC, the right DLPFC and was a sham treatment), participants completed tests to measure their response inhibition. For this purpose, the Eriksen-Flanker Task (EFT) or the Stop Signal Task (SST) were performed to assess interference cognitive control or action cancella-tion, respectively. Behavioral data (reaction time (RT), accuracy) and neurophysiological data (event-related potentials, ERPs) were also recorded. In the EFT, left-sided stimulation resulted in significantly  $faster RT compared to sham treatment (p &lt;0.0001) and right-sided stimulation (p =$ 0.0183). In the EFT, left-sided stimulation also modu-lated physiological measures, resulting in a significant increase in P300  $amplitude compared to sham (p =$ 0.022) and a significant decrease in  $N200 amplitude compared to right-sided stimulation (p =$ 0.027). Although a significant correlation was found between the RTs in the EFT  $and the ERPs (larger P200 amplitude (p =$ 0.046), and between larger  $P300 amplitudes (p =$ 0.046) and faster RT; smaller N200 amplitude and  $faster RT (p &lt;0.0001)), no significant differences were found in these$ relationships before vs. after stimulation. This finding suggests that tDCS may not significantly modulate the relationship between RT and ERPs. As for Stop trials in SST, no significant cognitive or physiological changes were found after left-sided stimulation. The authors interpreted these results with the hypothesis that tDCS targeting the left DLPFC could lead to an improvement in cognitive control but not in action cancellation.
<em>3.3.3. Physical activity</em> A RCT (NCT05049239) (Svedell et al., 2023) investigated the effects
of a 12-week exercise program in 14 adults with ADHD (aged 2754 years). The intervention consisted of a physiotherapist-led, small-group (46 participants) mixed exercise program with moderate to high in-tensity cardio, strength and flexibility exercises, targeting 60 %90 % of maximum heart rate, taking place for 50 min, three times a week for twelve weeks. When analysing the differences between pre- and post-treatment in the intervention group and the control group (who received usual care), significant improvement was found only in the intervention group. Compared to baseline, the intervention group actually showed a reduction in ADHD symptoms (significant as  $measured by the ASRS [p=0.036]; non-significant as measured by the CGI-S [p=0.11]), a general and significant improvement (determined by$ a composite score calculated from the scores of the Adult ADHD Self-Report Scale (ASRS), Clinical Global Impression-Severity (CGI-S), Patient Global Impression-Improvement (PGI-I), Montgomery-sberg Depression Rating Scale-Self-report (MADRS-S) and EQ visual analogue  $scaler (EQ-VAS) rating scales [p =$ 0.008]), and an improvement in  $cognitive functioning (significant, measured by the AX-CPT [p=0.032],$ non-significant for the Go/NoGo and emotion regulation tasks). Effect sizes were not reported.
<em>G.F. Veronesi et al.</em>
<em>NeuroscienceandBiobehavioralReviews163(2024)105774</em>
11
Completed RCTs of non-pharmacological treatments with positive results on at least one primary outcome and those with negative results on every primary outcome.
title Intervention type of intervention (neurostimulation, dietary, psychological, physical activity)
total n of arms control total n subjects
age range
trial duration
funding/ manufacturer
phase NCT number/ PMID
country start date
status descriptive results (primary outcome)
tolerability
Food Additives Effects on EEG Profiles in College Students With ADHD
Artificial Food Coloring
dietary 4 arms: 1) ADHD- Artificial food coloring, then placebo; 2) ADHD - Placebo, then artificial food coloring; 3) Controls- Artificial food coloring, then placebo; 4) Controls - Placebo, then artificial food coloring
placebo  29 18 Years to 24 Years (Adult)
6w American University
NA NCT03342469 United States
2018.01 COMPLETED WITH RESULTS
Not superior Serious adverse events: nil observed
Transcranial Magnetic Stimulation for Attention Deficit/ Hyperactivity Disorder (ADHD)
TMS neurostimulation 2 arms: Active TMS vs Sham TMS
Sham TMS  27 18 Years to 65 Years (Adult, Older Adult)
4w University of Pennsylvania
NA NCT03663179 United States
2017.01 COMPLETED WITH RESULTS
Not superior in reducing ADHD symptoms (CAARS-S:L); superior in improving sustained attention (mean [SD]: active  $TMS $ 16.2 [17.6]  $vs. sham TMS $ 4.8 [18.0]; Conners CPT)
Serious adverse events: nil observed in both arms. Not serious adverse events: 22.22 % in active TMS (Sleep disturbance 5.56 %; allergic reaction 5.56 %; Injury 5.56 %; Depression symptoms 5.56 %), and 7.14 % in sham TMS (Visual disturbance 7.14 %)
TDCS for the Treatment of Inattention Symptoms in Adult ADHD Patients (TUNED)
Home-based tDCS
neurostimulation 2 arms: Active tDCS vs Sham tDCS
Sham tDCS  64 18 Years and older (Adult, Older Adult)
12w Hospital de Clinicas de Porto Alegre
NA NCT04003740 Brazil  2019.07 COMPLETED WITH RESULTS
Superior in decreasing inattention (p  $&lt;0.001; ASRS)$
NA
Neuromodulation of Executive Function in the ADHD Brain
tDCS neurostimulation 2 arms: ADHD vs controls
controls  40 18 Years to 67 Years (Adult, Older Adult)
6w Massachusetts General Hospital
NA NCT04175028 PMID: 33549516
United States
2015.07 COMPLETED WITH RESULTS
Effects on executive functions: superior in improving RT in the EFT (p  $&lt;0.0001); non$ superior in the SST
NA
Structured Physical Training With and Without Cognitive
Physical training
physical activity 2 arms: Physical training vs TAU
TAU  14 27 Years to 54 Years
12 m Region rebro County
NA NCT05049239; PMID: 37255729
Sweden  2021.02 COMPLETED WITH RESULTS
Superior in reducing ADHD symptoms, as measured by ASRS
100 % of the participants in the experimental arm
<em>(continued on next page)</em>
<em>.F. Veronesi et al.</em>
<em>NeuroscienceandBiobehavioralReviews163(2024)105774</em>
12
title Intervention type of intervention (neurostimulation, dietary, psychological, physical activity)
total n of arms control total n subjects
age range
trial duration
funding/ manufacturer
phase NCT number/ PMID
country start date
status descriptive results (primary outcome)
tolerability
Support for Adults With ADHD
(Adult, Older Adult)
$(p=0.036), not$ superior by CGI-S; general  $improvement (p =$ 0.008; composite score*), improvement in cognitive functioning  $(p=0.032; AX-$ CPT)
considered the intervention physically strenuous, and 50 % of them considered it mentally strenuous. 100 % of trial participants reported overall health improvement.
Training Attentional Awareness and Control in ADHD (SAC-I)
Sustained Attention Control (SAC) Method
psychological 2 arms: SAC Method vs Control
Behavioral learning using the mobile software game &#34;Scrabble&#34;)
85 18 Years to 40 Years (Adult)
10w Think Now Incorporated
NA NCT02489279 United States
2015.06 COMPLETED WITH RESULTS
Superior in improving sustained attention  $(p =$ 0.026; Conners CPT RT Variability), timed reading comprehension (p  $=$ 0.014; NDRT),  $attention (p =$ 0.000001; ASRS),  $hyperactivity (p =$ 0.00018; ASRS)
Adverse events: nil observed
Improving ADHD Teen Driving
PC-based  $FOCAL+$ training
$psychological 2 arms: FOCAL +$ vs Control
modified conventional drivers training
152 16 Years to 19 Years (Child, Adult)
12 m . Childrens Hospital Medical Center, Cincinnati
NA NCT02848092; PMID: 36449421
United States
2016.12 COMPLETED WITH RESULTS
Superior in improving  $attention (P &lt;$ 0.001; reduction in the number of long glances away from the roadway); fewer collisions (RR, 0.60)
Motion sickness is reported during evaluation drives (0 % intervention group, 3 %control group), and during training drives (8 % intervention group, 5 % control group). Frustration with the simulator is reported in 3 % in the intervention group
The Secret Trail of Moon (Serious Videogame) and Chess on ADHD: a Clinal Trial
Cognitive Training with Virtual Reality Videogame (The Secret Trail of Moon) and Cognitive Traning with
psychological 3 arms: Cognitive Training with Virtual Reality Videogame (The Secret Trail of Moon) vs Cognitive Traning with Therapeutic Chess vs Control Group
TAU  105 12 Years to 22 Years (Child, Adult)
3 m Puerta de Hierro University Hospital
2 NCT04355065; PMID: 37093628
Spain  2019.12 COMPLETED WITH RESULTS
Superior in reducing inattentive symptoms and emotional  $dysregulation (p &lt;$ 0.10; CPT-3, ATENTO, BRIEF- 2).
NA
<em>(continued on next page)</em>
<em>.F. Veronesi et al.</em>
<em>NeuroscienceandBiobehavioralReviews163(2024)105774</em>
13
title Intervention type of intervention (neurostimulation, dietary, psychological, physical activity)
total n of arms control total n subjects
age range
trial duration
funding/ manufacturer
phase NCT number/ PMID
country start date
status descriptive results (primary outcome)
tolerability
Therapeutic Chess
Not superior in improving executive functions (BRIEF- 2).
Effects of Structured Skills Training Group in Treatment of ADHD in Adults
Structural skills training group
psychological 2 arms: Structural skills training group vs Treatment as usual
TAU  121 18 Years and older (Adult, Older Adult)
8 m University of Oslo
NA NCT02685254; PMID: 36443712
Norway  2016.02 COMPLETED Superior in decreasing ADHD  $symptoms (p &lt;$ 0.001; ASRS) and improving executive function  $(p=0.005; BRIEF-$ A). Not superior in improving emotional regulation (DERS)
Adverse events: nil observed
Group Dialectical Behavior Therapy as add-on Treatment for Adults With Attention Deficit/ Hyperactive Disorder
Skill Training Group of the Dialectical Behavior Therapy
psychological 2 arms: Group Dialectical Behavior Therapy vs treatment as usual
TAU  31 18 Years to 60 Years (Adult)
12w Hospital de Clinicas de Porto Alegre
NA NCT03326427; PMID: 32880953
Brazil  2018.04 COMPLETED WITH RESULTS
Not superior (ARSR)
NA
The Efficacy of Goal Focused, Non- Pharmacological Treatment for Persons With ADHD/ ADD
Goal Attainment Scaling
psychological 2 arms: Goal Attainment Scaling vs control group
TAU  81 18 Years to 60 Years (Adult)
12w University Hospital, Akershus
NA NCT04638283; PMID: 38046113
Norway  2019.08 COMPLETED WITH RESULTS
Not superior in improving executive functioning (BRIEF-A) or reducing ADHD symptoms (ARSR). Superior in decreasing anxiety  $symptoms (p =$ 0.014)
NA
CBT Through Internet and Smartphones for Adults With ADHD - a Randomized Controlled Trial (Ad5)
iCBT: A skill training internet-based treatment program based on CBT and DBT interventions
psychological 3 arms: iCBT vs iART vs TAU
iART; TAU  104 18 Years to 65 Years (Adult, Older Adult)
60w Karolinska Institutet
NA NCT02041884; PMID: 37483263
Sweden  2014.01 COMPLETED WITH RESULTS
$Superior (p&lt;0.01;$ ARSR), even 12 months after  $treatment (p &lt;$ 0.001). No significant difference between  $iCBT to iART (p =$ 0.53)
In iCBT, 8 % reported stress, 5 % depression, 5 % felt overwhelmed, 3 % felt discomfort. In iART, 11 % stress, 8 % anxiety, 3 % perceived the treatment as unclear, and % experienced somatic problems.
<em>(continued on next page)</em>
<em>.F. Veronesi et al.</em>
<em>NeuroscienceandBiobehavioralReviews163(2024)105774</em>
14
title Intervention type of intervention (neurostimulation, dietary, psychological, physical activity)
total n of arms control total n subjects
age range
trial duration
funding/ manufacturer
phase NCT number/ PMID
country start date
status descriptive results (primary outcome)
tolerability
Mindfulness Training in Adults With ADHD
MBCT psychological 2 arms: MBCT vs TAU
TAU  120 18 Years and older (Adult)
9 m Radboud University Medical Center
NA NCT02463396; PMID: 29486807
Netherlands  2014.09 COMPLETED WITH RESULTS
Superior in reducing ADHD  $symptoms (p =$ 0.004; CAARS), even 6 months after treatment, and in improving executive functions after 6 months (effect size  $of d =$ 0.49).
NA
An Internet- delivered Intervention for Coping With ADHD in Adulthood (MyADHD)
interventional MyADHD
psychological 2 arms: interventional MyADHD vs Psychoeducation
Psychoeducation  120 18 Years and older (Adult, Older Adult)
8w University of Bergen
NA NCT04726813; PMID: 36969389
Norway  2021.04 COMPLETED WITH RESULTS
Superior in improving ADHD  $symptoms (d =$ 0.70; ASRS) and  $quality of life (d =$ 0.53; AAQoL scale)
NA
Abbreviations: AAQoL: Adult ADHD Quality of Life ASRS: ADHD Self-Report Scale ATENTO questionnaire, BRIEF-2: Behavior Rating Inventory of Executive Function-2 CAARS-INV: SV: Conners Adult ADHD Rating Scale CAARS-S:L: Conners Adult ADHD Rating Scale - Self-Report: Long Version CGI-S: Clinical Global Impression-Severity Conners CPT RT Variability: Conners Continuous Performance Test Reaction Time Variability Conners CPT: Conners Continuous Performance Task CPT-3: Continuous Performance Test 3 EFT: Eriksen flanker task. FOCAL: Focused Concentration and Attention Learning iART:internet-based applied relaxation training iCBT: internet-based cognitive behavioral therapy MBCT: Mindfulness Based Cognitive Therapy NA: not applicable NDRT:Nelson Denny Reading Comprehension test RT: reaction time SST: stop signal task TAU: treatment as usual tDCS: transcranial direct current stimulation TMS: Transcranial Magnetic Stimulation *composite score: calculated from the scores of the ASRS, CGI-S, PGI-I, MADRS-S and EQ-VAS rating scales
<em>.F. Veronesi et al.</em>
<em>Neuroscience and Biobehavioral Reviews 163 (2024) 105774</em>
<em>3.3.4. Psychological therapies</em>
<em>3.3.4.1. Cognitive training.</em> One RCT (NCT02489279) tested two cognitive training programs on personal mobile devices that were used to assess the attention of 85 adults (58.7 % females, 1840 years old) with ADHD. Specifically, the Sustained Attention Control (SAC) mobile software, which tests sustained attention skills and self-awareness of attention control, was compared with the software game &#34;Scrabble&#34;,&#34; which is used to practice word processing and executive control func-tions. At the end of the 10-week treatment, significantly greater im-provements were found in the SAC group than in the active control group on both primary outcome measures, namely the measure of sus-tained attention (measured using the Conners Continuous Performance  $Test Reaction Time Variability (p =$ 0.026)) and timed reading  $comprehension (using the Nelson-Denny Reading Test (p =$ 0.014)).
In addition, the authors analysed the ADHD symptoms between the two groups using the Adult Attention-Deficit Hyperactivity Disorder Self-Report Scale (ASRS). The participants in the Scrabble group showed  $a greater improvement on the inattentive subscale (p =$ 0.000001) and  $the hyperactive subscale (p =$ 0.00018).
A computer-based training program referred to as FOcused Con- $centration and Attention Learning (FOCAL+) was developed to improve$ the attention of drivers with ADHD by trying to reduce their long glances  $(2 seconds) away from the roadway. A group of 152 participants (38 %$  <em>females) aged 1619 years (note; this study was included, as the sample encompassed individuals aged 18 or older) were randomised to either this</em> intervention group or the sham comparison group, which consisted of computerised training on traffic rules, laws, and regulations (NCT02848092) (Epstein et al., 2022)). Both the experimental and control training took place weekly for 5 weeks. During simulated driving after training, a significant reduction in the number of long glances away from the roadway was observed in the intervention group compared to  $the sham group after 1 month (P &lt; 0.001) and after 6 months (P &lt;$ 0.001). In addition, the rate of collisions and near-collisions during real driving was significantly lower in the intervention group one year after training (relative risk: 0.60).
Executive functions and emotional regulation were investigated in a group of 105 patients with ADHD (21.5 % females, aged 1222 years) who received either cognitive training with a virtual reality video game (The Secret Trail of Moon, TSTM group) or cognitive training with therapeutic chess (TC) or no cognitive intervention (control group, CG) (NCT04355065 (Rodrigo-Yanguas et al., 2023)). Notably statistical  $threshold was set and reported in this study at p &lt;0.10. Compared to the$ CG group, the TC group performed significantly better in terms of  $emotional control, emotional regulation, and inattention (p &lt;$ 0.10). On the other hand, the TSTM group showed significantly better improve- $ments compared to the CG group (p &lt;0.10) on the measures of$ emotional regulation, inattention, and school context.
<em>3.3.4.2. Dialectical behavioural therapy-based group treatment.</em> A study investigated the effects of 14 weeks of Dialectical Behavioural Therapy- based Group Treatment (DBT-bGT) compared to treatment as usual (TAU) on executive functions and emotional regulation in adults with  $ADHD (n =$ 121, 56 % females) (NCT02685254) (Halmy et al., 2022). Although emotional regulation (measured with the Difficulties in Emotion Regulation Scale, DERS) did not differ significantly between the groups, significant improvements in executive functions were found in the DBT-bGT group using the Behaviour Rating Inventory of Execu- $tive Function (BRIEF-A) (p =$ 0.005). Compared to participants receiving TAU, those assigned to DBT-bGT reported significant improvement in  $ADHD core symptoms (ASRS total score, p &lt;$ 0.001), depressive symp- $toms (BDI total score, p &lt;$ 0.001), and quality of life (AAQol total score,  $p =$ 0.004). However, DBT-bGT was not superior to TAU in reducing anxiety symptoms. The authors also found that these observed symptom
reductions persisted in the DBT-bGT group at the 6-month follow-up. Effect sizes were not reported.
The efficacy of the Dialectical Behavior Therapy Skill Training Group (DBT-ST) was compared as an add-on treatment to ADHD medication vs to treatment as usual (TaU) in another study (NCT03326427) (Moritz et al., 2021)) involving 31 adults with ADHD (aged 18 and 60 years). After participating in 12 weeks of DBT-ST or TaU, ADHD symptoms were assessed using the ADHD Self-Rating Scale (ASRS). No significant dif-ference was found between the groups in ASRS scores over time.
<em>3.3.4.3. Goal management training.</em> Goal Management Training (GMT) was compared with Treatment as usual (TAU) in improving executive functions and reducing ADHD symptoms and comorbidity (NCT04638283) (Hanssen et al., 2023). In this study, the active inter-vention consisted of 16 hours of GMT and psychoeducation plus 4 in- $dividual sessions focusing on specific goals. Adults with ADHD (n =$ 81; aged 1855 years; 58 % women; 23.5 % diagnosed with anxiety) were randomly assigned to either GMT or TAU. In both groups, executive functions, psychological well-being, and ADHD symptoms were assessed from baseline to 8-month follow-up. A significantly greater decrease in anxiety symptoms was found in the GMT compared to the TAU group (p  $= 0.014, measured with HSCL-25, anxiety; p =$ 0.048 with HSCL-25, total). Conversely, no statistically significant difference was found be-tween the two groups in improvement in daily executive functioning (BRIEF-A) or reduction in ADHD symptom intensity (ASRS-v1.1).
<em>3.3.4.4. Internet-based cognitive behavioural therapy.</em> In 2104 adults (1865 years) with ADHD (69 % females), internet-based cognitive behavioural therapy (iCBT) was compared to internet-based applied relaxation training (iART) and treatment as usual (TAU) (NCT02041884) (Nasri et al., 2023). The change in scores on the Adult ADHD Self-Report Scale (ASRS), consisting of the two subscales of inattention and hyperactivity/impulsivity, was tested after 12 weeks of treatment (post-treatment) and 3 and 12 months after the end of treat- $ment. ASRS scores improved significantly more with both iCBT (p &lt; 0.01; Cohens d =$ 0.42 at post-treatment and 0.67 at 3 months) and  $iART (p &lt; 0.01; Cohens d =$ 0.57 at post-treatment and 0.66 at 3 months) than with TAU. These improvements persisted over 12 months  $with both iCBT (p &lt; 0.001) and iART (p &lt;$ 0.001). However, no sig-nificant differences were found between the iCBT and iART groups.
<em>3.3.4.5. Mindfulness-based cognitive therapy.</em> Mindfulness-based cogni-tive therapy (MBCT), consisting of an 8-week group therapy with meditation exercises, psychoeducation, and group discussion, in addi-tion to treatment as usual (TAU, i.e., pharmacotherapy and/or psycho-education), was compared with TAU only in terms of core symptom reduction in one RCT (NCT02463396) involving 120 participants  $(Janssen et al., 2019). In the experimental arm (MBCT +$ TAU), a sig- $nificant decrease in ADHD symptoms was observed after treatment (p =$ 0.004), and this significant difference remained stable during the  $6-month follow-up period. In addition, more patients in the MBCT + TAU group showed a symptom reduction of 30 % (p =$ 0.001) or  $symptomatic remission (p =$ 0.039) compared to the TAU group.  $Although patients in the MBCT +$ TAU group reported no improvement in executive functions immediately after treatment compared to the TAU group, the difference between the groups became significant over the  $6-month follow-up period (effect size: d =$ 0.49).
<em>3.3.4.6. Self-guided psychological internet-delivered intervention.</em> The ef-ficacy of a self-guided psychological internet-delivered intervention on ADHD symptom severity and quality of life in adults with ADHD was compared with a control intervention consisting of an online psycho-education module (NCT04726813) (Kenter et al., 2023)). A sample with
<em>G.F. Veronesi et al.</em>
<em>Neuroscience and Biobehavioral Reviews 163 (2024) 105774</em>
$self-reported ADHD diagnoses (N =$ 120, 80 % females) was randomly assigned to one of these two groups. When comparing the two groups, a  $moderate to large improvement in ADHD symptoms (d =$ 0.70) and  $quality of life (d =$ 0.53) was found for the Self-guided psychological internet-delivered intervention, these effects also persisted at the  $3-month follow-up (d = 0.76 and d =$ 0.52).
<em>3.3.5. Non-pharmacological treatments in RCT with results of statistical analysis not reported</em>
Non-pharmacological treatments in RCTs (other than those described above) with results of statistical analysis not reported for  <em>ADHD core symptoms or other outcomes included: psychological thera-pies: CBT (3 RCTs) (2 RCTs), iCBT (2 RCTs), working memory training,</em> cognitive training, programme aimed at strengthening resilience, con-tingency management, structural skills training (2 RCTs), psycho- $education (in 2 RCTs), psychoeducation+Brief Motivational$ Interviewing and Behavioral Activation, dCBTi, occupational Therapy, training via videogame, Mindfulness (3 RCTs), Acceptance and Commitment-Therapy, neurofeedback (3 RCts), digital self-help, Goal Attainment Scaling, online self-compassion intervention, FOCUS ADHD App, cognitive behavioral therapy and Motor Learning Techniques;  <em>lifestyle: tai chi and exercise, structured aerobic exercise, Bright light</em> therapy, physical exercise (2 RCTs), fidget ball, transdiagnostic sleep  <em>and circadian treatment; dietary interventions: highly unsaturated omega-</em> 3 fatty acids (RCT terminated), fish oil, Rhodiola rosea (2 RCTs), oli- <em>gopin; neurostimulation: rTMS, tDCS (6 RCTs), home-based transcranial</em> direct current stimulation, Magnetic EEG/ ECG-Guided Resonance Therapy (MeRT), active transcranial photobiomodulation (t-PBM) (2 RCTs), and functional near-infrared spectroscopy (fNIRS)-based neuro-feedback (NF).
<strong>4. Discussion</strong>
To our knowledge, this is the first systematic review of ongoing or completed (in the last decade) RCTs of pharmacological or non- pharmacological treatments for ADHD in adults, providing an over-view on recent developments in the field and treatments in the pipeline. When considering the overall body of RCTs of interventions for adult ADHD that have been registered over the past decade, it is striking that only around 30 % tested a pharmacological treatment, while the ma-jority (nearly 70 %) explored the efficacy/safety of non-pharmacological options. This situation likely reflects two main aspects. First, the notion that currently available medications for the management of ADHD are quite effective for ADHD symptoms but have a symptomatic, rather than curative, action. Second, concerns around possible side effects of med-ications, in particular stimulants, including cardiovascular safety and abuse potential. However, it is interesting to note that amphetamines in adults have been found to have better acceptability than placebo in network meta-analytic evidence (Cortese et al., 2018). Furthermore, in relation to the potentially most concerning side effect of stimulant, i.e., cardiovascular safety, recent evidence from the large observational study with the longest follow-up indicated that longer cumulative use of methylphenidate for up to 14 years was correlated with a statistically significant but overall small increased risk of hypertension and arterial disease, but not of other serious cardiovascular conditions, such as heart failure (Zhang et al., 2024).
From the body of 90 RCT eligible for the present review (after dis-carding 25 RCTs of pharmacological compounds approved by the FDA and hence used in clinical practice) identified in clinical trial registries,  $about 27 % (n =$ 24) reported results with statistical analysis. From these RCTs, positive results in single trials for ADHD core symptoms were identified, in relation to pharmacological treatments, for centanafadine, mazindol, OPC-64005, solriamfetol, and, regarding non-pharmacological options, for rTMS, tDCS, physical activity, DBT, iCBT, mindfulness and self-guided support. However, when considering positive results repli-cated in at least one additional independent RCT, only centanafadine had
this level of evidence, and the effect sizes were small (0.24, 0.28, 0.37, and 0.40) across the 4 active arms with positive results.
Focusing on pharmacological treatments, more specifically, the ef-fect size found for non- stimulant compounds were generally small, with two isolated trials having large effect sizes of 1.1 (mazindol, solriamfetol isazol), but without replication (mazindol) or even with a trial without results reported (solriamfetol isazol), likely indicating non-significant or small effect. While it would be desirable to have compounds with effect size as high as those of stimulants (one of the highest effect sizes across psychiatry and more generally medicine, at least in the short term), being 0.79 for amphetamines and for 0.49 methylphenidate in adults (Cortese et al., 2018), and better tolerability profile, this has not been achieved yet. This state of affairs is not dissimilar from the situation in relation to medications in the pipeline for children. In the previous re-view focused on recent (last 10 years) registered phase II, III, or IV RCTs in children (Cortese et al., 2023b), only dasotraline had positive evi-dence, replicated in at least one additional RCT, of superiority versus placebo, with a small-moderate effect size (~0.4). In contrast, dasotra-line was not superior in the trial in adults with ADHD when correcting for multiple comparisons, as summarized above.
An interesting development in the field, that may eventually lead to even more effective, well tolerated and possibly curative pharmaco- <em>logical treatments is represented by research on the so-called druggable genome, which refers to as a selection of genes that are potential targets</em> for pharmacological interventions. Interestingly, through the analysis of data derived from genome-wide analyses (GWA) of ADHD, it has been discovered that none of the genes responsible for the primary targets of first-line pharmacotherapeutics for ADHD exhibited significant associ-ation with the disorder (Hegvik et al., 2021). This finding implies that FDA-approved ADHD medications might operate through mechanisms distinct from those underlying ADHD. Remarkably, three specific loci on chromosomes 1, 4, and 12 exhibited significant association with ADHD and harbored nine genes susceptible to pharmacological intervention, five of which encode well-established drug targets for conditions such as malignancies, autoimmune disorders, and neurodevelopmental disor-ders (Hegvik et al., 2021).
While we excluded from this review RCTs on compounds that are FDA approved, we highlight that an important area of research is rep-resented by the additional development of formulations of already approved compounds that can have a longer duration of action and/or that can lead to a better adherence (such as liquid or chewable formu-lations), as well as formulations that are active in the early hours of the day, or patches. Indeed, adherence is a crucial issue in the pharmaco-logical treatment of ADHD. During the 12-month follow-up periods examined in multiple studies within a systematic review of 91 original studies (Gajria et al., 2014), the mean duration of stimulant treatment was found to be 136 days for children and 230 days for adults. Notably, the highest rates of medication discontinuation were observed among individuals aged 1521 years (Zetterqvist et al., 2013). Reasons cited for discontinuation encompassed side effects, perceived inefficacy, aversion to medication intake, determination of unnecessary treatment, social stigma, and challenges associated with transitioning from paediatric to adult healthcare services. Another issue to consider in future RCTs is around the length of the RCT. As the average length of currently avail-able or planned RCTs is usually limited to a few weeks, the evidence they generate is not suitable to inform clinical decision making in the longer-term. While longer-term RCTs may be challenging due to logistic and ethical reasons (in terms of randomising participants to placebo over a sustained period of time when active medication is superior to placebo), discontinuation RCTs, where individuals treated with active medication for months or years are randomised for a short period to continuation of active treatment or switch to placebo should be encouraged. Another important aspect to bear in mind when planning future RCTs is sex/gender balance in terms of recruitment. We note that, compared to RCTs in children, those in adults have in general a more balanced recruitment in terms sex/gender, probably reflecting the more
<em>G.F. Veronesi et al.</em>
<em>Neuroscience and Biobehavioral Reviews 163 (2024) 105774</em>
balanced sex/gender ratio in the diagnosis of ADHD in adults compared to children. In fact, while, due to a referral bias, boys, who tend to be more hyperactive than girls, are referred more frequently to clinical services for ADHD, in adulthood women who struggle mainly with inattentive presentation of ADHD are more prone to consult an ADHD specialist due to the impact of inattention and additional comorbidities that are highly frequent in adulthood (Cortese et al., 2016).
Finally, future RTs will need to address placebo effects, that have been shown to be present also in RCTs of medications for ADHD (Far-aone et al., 2022). Evidence primarily derived from RCTs in schizo-phrenia indicates that certain factors enhance the likelihood of distinguishing between drug and placebo effects. These factors have led to the following recommendations: refrain from incorporating an open-label lead-in phase prior to randomization in general; minimize the number of study sites, active treatment arms, and participants; randomly allocate more participants to the placebo group, thereby reducing the expectancy bias associated with receiving an active intervention; consider employing an extended wash-out period after discontinuation of previous medication, if feasible and ethically sound given the con-dition; utilize validated diagnostic and symptom rating tools; conduct trials lasting longer than four weeks in acute settings; and include in-dividuals severely affected by the condition as well as those experi-encing a first episode or with shorter illness durations (Cortese et al., 2024; Correll et al., 2023). Additionally, regarding placebo, we suggest that researchers will need to consider possible ethical implications of testing active medications vs placebo when efficacious treatments are already available in the market.
Regarding non-pharmacological treatments, even though no indi-vidual treatment had evidence of superiority versus control for ADHD core symptoms in more than one RCT, the field looks forward to the results of an increasing body of ongoing RCTs on a variety of non- pharmacological interventions, spanning from psychological to dietary treatments and neurostimulation. Two possible developments in the field are of potential interest. First, the development of digital delivery, arguably fostered by the COVID-19 pandemic, of approaches tradition-ally delivered face-to-face, such as iCBT, which, however, needs addi-tional evidence. Second, the development of more sophisticated or alternative versions of existing treatments, such as, just to cite two ex-amples: 1) novel and unusual types of psychotherapy, such as brief motivational interviewing and behavioral activation, or acceptance and commitment-therapy; 2) functional near-infrared spectroscopy (fNIRS)- based neurofeedback (NF). However, after decades of research on neu-rofeedback, there is no solid evidence that it can significantly change ADHD core symptoms when considering blinded outcomes (Coghill et al., 2023) (Sonuga-Barke et al., 2013), reflecting the findings in relation to other non-pharmacological approaches, such as cognitive training (Westwood et al., 2023) and behavioral interventions (Daley et al., 2014) in children. It is possible that novel neurofeedback ap-proaches and protocol are more efficacious, but this possibility needs rigorous RCT and meta-analytic evidence.
Notably, for some non-pharmacological treatments it is challenging or virtually impossible to blind the trial. A series of meta-analyses by the European ADHD Guidelines Group (EAGG) (Sonuga-Barke et al., 2013; Westwood et al., 2023; Daley et al., 2014; Cortese et al., 2015; Cortese et al., 2016) focused on children with ADHD has established that, while, when considering probably blinded outcomes many non-pharmacological treatments are not more efficacious than control in terms of ADHD core symptoms, they may be efficacious for some out-comes, such as executive dysfunction for cognitive training (Westwood et al., 2023), or parenting for parent training behavior (Daley et al., 2014). Future RCTs of non-pharmacological treatments of adults with ADHD should take this possible discrepancy into account, by carefully assessing effects on core and non-core symptoms. While some unusual outcomes of interest have been recently examined (such as the number of long glances away from the roadway (Epstein et al., 2022)) with a computerized skills-training program, which significantly reduced the
relevant endpoint of accidents, other increasingly relevant outcomes, such as quality of life, remain still underrepresented in ADHD RCTs (both of pharmacological and non-pharmacological treatments).
In addition to shorter-term RCTs, mainly aimed at obtaining regu-latory approval, like those included in the present review, the field will need also pragmatic, longer-term RCTs, withdrawal RCTs and, crucially, comparative studies including pharmacological and non- pharmacological options, as well as RCTs examining the most effective sequencing or combination(s) of pharmacological and non- pharmacological treatments.
This study should be considered in light of some limitations. First, we systematically searched https://clinicaltrials.gov/and and https://www .clinicaltrialsregister.eu/ but not other national registries, which would have been unpractical. Second, we limited the search to 01/01/ 201010/18/2023, to cover a recent time span, but other search dates would have been also an option. Third, it was beyond the scope of the present work to systematically contact study authors or pharmaceutical companies to inquiry about the status of the trials and their results. Lastly, we did not systematically check any discrepancy between data reported in the publication and what was planned, which is the focus on another ongoing work from our group.
Despite these limitations, this review provided the currently most rigorous overview of RCTs of pharmacological and non-pharmacological treatments for adults with ADHD. Since to date no treatments more efficacious and safer the stimulants have been identified and given the frequency and relevance of ADHD in adults, it is important to continue developing and testing additional treatments for adults with ADHD seeking other effective and well tolerated treatments, and possibly curative intervention strategies.
<strong>Data availability</strong>
Data will be made available on request.
<strong>Acknowledgements</strong>
Samuele Cortese, NIHR Research Professor (NIHR303122) is funded by the NIHR for this research project. The views expressed in this pub-lication are those of the author(s) and not necessarily those of NIHR, NHS or the UK Department of Health and Social Care. Samuele Cortese is also supported by NIHR grants NIHR203684, NIHR203035, NIHR130077, NIHR128472, RP-PG-0618-20003 and by grant 101095568-HORIZONHLTH- 2022-DISEASE-07-03 from the European Research Executive Agency.
<strong>Appendix A. Supporting information</strong>
Supplementary data associated with this article can be found in the online version at doi:10.1016/j.neubiorev.2024.105774.
<strong>References</strong>
Adler, L.A., Goldman, R., Hopkins, S.C., Koblan, K.S., Kent, J., Hsu, J., Loebel, A., 2021. Dasotraline in adults with attention deficit hyperactivity disorder: a placebo- controlled, fixed-dose trial. Int Clin. Psychopharmacol. 36 (3), 117125.
Adler, L.A., Adams, J., Madera-Mcdonough, J., Kohegyi, E., Hobart, M., Chang, D., Angelicola, M., Mcquade, R., Liebowitz, M., 2022. Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/ Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials. J. Clin. Psychopharmacol. 42, 429439.
Arrondo, G., Solmi, M., Dragioti, E., Eudave, L., Ruiz-Goikoetxea, M., Ciaurriz-Larraz, A. M., Magallon, S., Carvalho, A.F., Cipriani, A., Fusar-Poli, P., Larsson, H., Correll, C. U., Cortese, S., 2022. Associations between mental and physical conditions in children and adolescents: An umbrella review. Neurosci. Biobehav Rev. 137, 104662.
Ayano, G., Tsegay, L., Gizachew, Y., Necho, M., Yohannes, K., Abraha, M., Demelash, S., Anbesaw, T., Alati, R., 2023. Prevalence of attention deficit hyperactivity disorder in adults: Umbrella review of evidence generated across the globe. Psychiatry Res 328, 115449.
<em>G.F. Veronesi et al.</em>
<em>Neuroscience and Biobehavioral Reviews 163 (2024) 105774</em>
Biederman, J., Lindsten, A., Sluth, L.B., Petersen, M.L., Ettrup, A., Eriksen, H.F., Fava, M., 2019. Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study. J. Psychopharmacol. 33, 511521.
Buitelaar, J.K., Van De Loo-Neus, G.H.H., Hennisen, L., et al., 2022. ADDUCE consortium. Long-term methylphenidate exposure and 24-hours blood pressure and left ventricular mass in adolescents and young adults with attention deficit hyperactivity disorder. Eur. Neuropsychopharmacol. 64, 6371.
Coghill, D., Banaschewski, T., Cortese, S., Asherson, P., Brandeis, D., Buitelaar, J., Daley, D., Danckaerts, M., Dittmann, R.W., Doepfner, M., Ferrin, M., Hollis, C., Holtmann, M., Paramala, S., Sonuga-Barke, E., Soutullo, C., Steinhausen, H.C., Van Der Oord, S., Wong, I.C.K., Zuddas, A., Simonoff, E., 2023. The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG). Eur. Child Adolesc. Psychiatry 32, 13371361.
Cohen, J., 1988. Statistical Power Analysis for the Behavioral Sciences. Routledge Academic,, New York, NY.
Cooper, R.E., Williams, E., Seegobin, S., Tye, C., Kuntsi, J., Asherson, P., 2017. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Eur. Neuropsychopharmacol. 27, 795808.
Correll, C.U., Solmi, M., Cortese, S., Fava, M., Hjlund, M., Kraemer, H.C., Mcintyre, R.S., Pine, D.S., Schneider, L.S., Kane, J.M., 2023. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry 22, 4874.
Cortese, S., 2020. Pharmacologic Treatment of Attention Deficit-Hyperactivity Disorder. N. Engl. J. Med 383, 10501056.
Cortese, S., Fava, C., 2024. Long-Term Cardiovascular Effects of Medications for Attention-Deficit/Hyperactivity Disorder-Balancing Benefits and Risks of Treatment. JAMA Psychiatry 81, 123124.
Cortese, S., Ferrin, M., Brandeis, D., Buitelaar, J., Daley, D., Dittmann, R.W., Holtmann, M., Santosh, P., Stevenson, J., Stringaris, A., Zuddas, A., Sonuga-Barke, E. J., 2015. Cognitive training for attention-deficit/hyperactivity disorder: meta- analysis of clinical and neuropsychological outcomes from randomized controlled trials. J. Am. Acad. Child Adolesc. Psychiatry 54, 164174.
Cortese, S., Faraone, S.V., Bernardi, S., Wang, S., Blanco, C., 2016. Gender differences in adult attention-deficit/hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). J. Clin. Psychiatry 4, e421e428.
Cortese, S., Ferrin, M., Brandeis, D., Holtmann, M., Aggensteiner, P., Daley, D., Santosh, P., Simonoff, E., Stevenson, J., Stringaris, A., Sonuga-Barke, E.J., 2016. Neurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials. J. Am. Acad. Child Adolesc. Psychiatry 55, 444455.
Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A.J., Carucci, S., Atkinson, L.Z., Tessari, L., Banaschewski, T., Coghill, D., Hollis, C., Simonoff, E., Zuddas, A., Barbui, C., Purgato, M., Steinhausen, H.C., Shokraneh, F., Xia, J., Cipriani, A., 2018. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5, 727738.
Cortese, S., Song, M., Farhat, L.C., Yon, D.K., Lee, S.W., Kim, M.S., Park, S., Oh, J.W., Lee, S., Cheon, K.A., Smith, L., Gosling, C.J., Polanczyk, G.V., Larsson, H., Rohde, L. A., Faraone, S.V., Koyanagi, A., Dragioti, E., Radua, J., Carvalho, A.F., Il Shin, J., Solmi, M., 2023. Incidence, prevalence, and global burden of ADHD from 1990 to 2019 across 204 countries: data, with critical re-analysis, from the Global Burden of Disease study. Mol. Psychiatry 28, 48234830.
Cortese, S., Mcginn, K., Hjlund, M., Apter, A., Arango, C., Baeza, I., Banaschewski, T., Buitelaar, J., Castro-Fornieles, J., Coghill, D., Cohen, D., Grnblatt, E., Hoekstra, P. J., James, A., Jeppesen, P., Nagy, P., Pagsberg, A.K., Parellada, M., Persico, A.M., Purper-Ouakil, D., Roessner, V., Santosh, P., Simonoff, E., Stevanovic, D., Stringaris, A., Vitiello, B., Walitza, S., Weizman, A., Wohlfarth, T., Wong, I.C.K., Zalsman, G., Zuddas, A., Moreno, C., Solmi, M., Correll, C.U., 2023b. The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications. Neurosci. Biobehav Rev. 149, 105149.
Cortese, S., Purper-Ouakil, D., Apter, A., Arango, C., Baeza, I., Banaschewski, T., Buitelaar, J., Castro-Fornieles, J., Coghill, D., Cohen, D., Correll, C.U., Grnblatt, E., Hoekstra, P.J., James, A., Jeppesen, P., Nagy, P., Pagsberg, A.K., Parellada, M., Persico, A.M., Roessner, V., Santosh, P., Simonoff, E., Stevanovic, D., Stringaris, A., Vitiello, B., Walitza, S., Weizman, A., Wong, I.C.K., Zalsman, G., Zuddas, A., Carucci, S., Butlen-Ducuing, F., Tome, M., Bea, M., Getin, C., Hovn, N., Konradsson- Geuken, A., Lamirell, D., Olisa, N., Nafria Escalera, B., Moreno, C., 2024. Psychopharmacology in children and adolescents: unmet needs and opportunities. Lancet Psychiatry 11, 143154.
Daley, D., Van Der Oord, S., Ferrin, M., Danckaerts, M., Doepfner, M., Cortese, S., Sonuga-Barke, E.J., 2014. Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across multiple outcome domains. J. Am. Acad. Child Adolesc. Psychiatry 53 (835-47), 847.e1-5.
Dubreuil-Vall, L., Gomez-Bernal, F., Villegas, A.C., Cirillo, P., Surman, C., Ruffini, G., Widge, A.S., Camprodon, J.A., 2021. Transcranial Direct Current Stimulation to the Left Dorsolateral Prefrontal Cortex Improves Cognitive Control in Patients With Attention-Deficit/Hyperactivity Disorder: A Randomized Behavioral and Neurophysiological Study. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 6, 439448.
Epstein, J.N., Garner, A.A., Kiefer, A.W., Peugh, J., Tamm, L., Macpherson, R.P., Simon, J.O., Fisher, D.L., 2022. Trial of Training to Reduce Driver Inattention in Teens with ADHD. N. Engl. J. Med 387, 20562066.
Faraone, S.V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M.A., Newcorn, J.H., Gignac, M., Al Saud, N.M., Manor, I., Rohde, L.A., Yang, L., Cortese, S., Almagor, D., Stein, M.A., Albatti, T.H., Aljoudi, H.F., Alqahtani, M.M.J., Asherson, P., Atwoli, L., Blte, S., Buitelaar, J.K., Crunelle, C.L., Daley, D., Dalsgaard, S., Dpfner, M., Espinet, S., Fitzgerald, M., Franke, B., Gerlach, M., Haavik, J., Hartman, C.A., Hartung, C.M., Hinshaw, S.P., Hoekstra, P.J., Hollis, C., Kollins, S.H., Sandra Kooij, J.J., Kuntsi, J., Larsson, H., Li, T., Liu, J., Merzon, E., Mattingly, G., Mattos, P., Mccarthy, S., Mikami, A.Y., Molina, B.S.G., Nigg, J.T., Purper-Ouakil, D., Omigbodun, O.O., Polanczyk, G.V., Pollak, Y., Poulton, A.S., Rajkumar, R.P., Reding, A., Reif, A., Rubia, K., Rucklidge, J., Romanos, M., Ramos- Quiroga, J.A., Schellekens, A., Scheres, A., Schoeman, R., Schweitzer, J.B., Shah, H., Solanto, M.V., Sonuga-Barke, E., Soutullo, C., Steinhausen, H.C., Swanson, J.M., Thapar, A., Tripp, G., Van De Glind, G., Van Den Brink, W., Van Der Oord, S., Venter, A., Vitiello, B., Walitza, S., Wang, Y., 2021. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neurosci. Biobehav Rev. 128, 789818.
Faraone, S.V., Newcorn, J.H., Cipriani, A., Brandeis, D., Kaiser, A., Hohmann, S., Haege, A., Cortese, S., 2022. Placebo and nocebo responses in randomised, controlled trials of medications for ADHD: a systematic review and meta-analysis. Mol. Psychiatry 27, 212219.
Faraone, S.V., Bellgrove, M.A., Brikell, I., Cortese, S., Hartman, C.A., Hollis, C., Newcorn, J.H., Philipsen, A., Polanczyk, G.V., Rubia, K., Sibley, M.H., Buitelaar, J.K., 2024. Attention-deficit/hyperactivity disorder. Nat. Rev. Dis. Prim. 10, 11.
Gajria, K., Lu, M., Sikirica, V., Greven, P., Zhong, Y., Qin, P., Xie, J., 2014. Adherence, persistence, and medication discontinuation in patients with attention-deficit/ hyperactivity disorder - a systematic literature review. Neuropsychiatr. Dis. Treat. 10, 15431569.
Halmy, A., Ring, A.E., Gjestad, R., Mller, M., Ubostad, B., Lien, T., Munkhaugen, E.K., Fredriksen, M., 2022. Dialectical behavioral therapy-based group treatment versus treatment as usual for adults with attention-deficit hyperactivity disorder: a multicenter randomized controlled trial. BMC Psychiatry 22, 738.
Hanssen, K.T., Brevik, E.J., Smstuen, M.C., Stubberud, J., 2023. Improvement of anxiety in ADHD following goal-focused cognitive remediation: a randomized controlled trial. Front Psychol. 14, 1212502.
Hegvik, T.A., Walen, K., Pandey, S.K., Faraone, S.V., Haavik, J., Zayats, T., 2021. Druggable genome in attention deficit/hyperactivity disorder and its co-morbid conditions. New avenues for treatment. Mol. Psychiatry 26, 40044015.
Janssen, L., Kan, C.C., Carpentier, P.J., Sizoo, B., Hepark, S., Schellekens, M.P.J., Donders, A.R.T., Buitelaar, J.K., Speckens, A.E.M., 2019. Mindfulness-based cognitive therapy v. treatment as usual in adults with ADHD: a multicentre, single- blind, randomised controlled trial. Psychol. Med 49, 5565.
Kenter, R.M.F., Gjestad, R., Lundervold, A.J., Nordgreen, T., 2023. A self-guided internet- delivered intervention for adults with ADHD: Results from a randomized controlled trial. Internet Inter. 32, 100614.
Lam, N.S.K., Long, X.X., Li, X., Saad, M., Lim, F., Doery, J.C., Griffin, R.C., Galletly, C., 2022. The potential use of folate and its derivatives in treating psychiatric disorders: A systematic review. Biomed. Pharm. 146, 112541 (Feb).
Moritz, G.R., Pizutti, L.T., Cancian, A.C.M., Dillenburg, M.S., De Souza, L.A.S., Lewgoy, L. B., Basso, P., Andreola, M.M.P., Bau, C.H.D., Victor, M.M., Teche, S.P., Grevet, E.H., Philipsen, A., Rohde, L.A.P., 2021. Feasibility trial of the dialectical behavior therapy skills training group as add-on treatment for adults with attention-deficit/ hyperactivity disorder. J. Clin. Psychol. 77, 516524.
Nasri, B., Cassel, M., Enhrje, J., Larsson, M., Hirvikoski, T., Ginsberg, Y., Lindefors, N., Kaldo, V., 2023. Internet delivered cognitive behavioral therapy for adults with ADHD - A randomized controlled trial. Internet Inter. 33, 100636.
NATIONAL INSTITUTE FOR HEALTH And Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis And management (NICE guideline NG87) 2019 [Available from: https://www.nice.org.uk/guidance/ng87.
Rodrigo-Yanguas, M., Martn-Moratinos, M., Gonzlez-Tardn, C., Sanchez-Sanchez, F., Royuela, A., Bella-Fernndez, M., Blasco-Fontecilla, H., 2023. Effectiveness of a Personalized, Chess-Based Training Serious Video Game in the Treatment of Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder: Randomized Controlled Trial. JMIR Serious Games 11, e39874.
Sibley, M.H., Mitchell, J.T., Becker, S.P., 2016. Method of adult diagnosis influences estimated persistence of childhood ADHD: a systematic review of longitudinal studies. Lancet Psychiatry 3, 11571165.
Song, P., Zha, M., Yang, Q., Zhang, Y., Li, X., Rudan, I., 2021. The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta- analysis. J. Glob. Health 11, 04009.
Sonuga-Barke, E.J., Brandeis, D., Cortese, S., Daley, D., Ferrin, M., Holtmann, M., Stevenson, J., Danckaerts, M., Van Der Oord, S., Dpfner, M., Dittmann, R.W., Simonoff, E., Zuddas, A., Banaschewski, T., Buitelaar, J., Coghill, D., Hollis, C., Konofal, E., Lecendreux, M., Wong, I.C., Sergeant, J., 2013. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am. J. Psychiatry 170, 275289.
Surman, C.B.H., Walsh, D.M., Horick, N., Disalvo, M., Vater, C.H., Kaufman, D., 2023. Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults: A Double-Blind Placebo-Controlled Pilot Study. J. Clin. Psychiatry 84.
Svedell, L.A., Holmqvist, K.L., Lindvall, M.A., Cao, Y., Msghina, M., 2023. Feasibility and tolerability of moderate intensity regular physical exercise as treatment for core symptoms of attention deficit hyperactivity disorder: a randomized pilot study. Front Sports Act. Living 5, 1133256.
Westwood, S.J., Parlatini, V., Rubia, K., Cortese, S., Sonuga-Barke, E.J.S., 2023. Computerized cognitive training in attention-deficit/hyperactivity disorder (ADHD):
<em>G.F. Veronesi et al.</em>
<em>Neuroscience and Biobehavioral Reviews 163 (2024) 105774</em>
a meta-analysis of randomized controlled trials with blinded and objective outcomes. Mol. Psychiatry 28, 14021414.
Wigal, S.B., Wigal, T., Hobart, M., Madera, J.J., Baker, R.A., Kohegyi, E., Mckinney, A., Wilens, T.E., 2020. Safety and efficacy of centanafadine sustained-release in adults with attention-deficit hyperactivity disorder: results of phase 2 studies. Neuropsychiatr. Dis. Treat. 16, 14111426.
Wigal, T.L., Newcorn, J.H., Handal, N., Wigal, S.B., Mulligan, I., Schmith, V., Konofal, E., 2018. A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation
of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD). CNS Drugs 32, 289301.
Zetterqvist, J., Asherson, P., Halldner, L., Lngstrm, N., Larsson, H., 2013. Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006-2009. Acta Psychiatr. Scand. 128, 7077.
Zhang, L., Li, L., Andell, P., Garcia-Argibay, M., Quinn, P.D., Donofrio, B.M., Brikell, I., Kuja-Halkola, R., Lichtenstein, P., Johnell, K., Larsson, H., Chang, Z., 2024. Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry 81, 178187.
<em>G.F. Veronesi et al.</em></li>
</ol>
